Stopping myeloma maintenance after two years shows no survival loss in trial

medicalxpress - For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment. A randomized phase 3…

AI Summary: Long‑term follow‑up from a randomized multiple myeloma maintenance study indicates that stopping lenalidomide after two years yields similar overall survival to continuing indefinitely. The data support a limited‑duration maintenance strategy that may spare patients toxicity and costs without sacrificing outcomes — revolutionary for weary patients and budget‑conscious oncologists alike.